U.S. Attorney’s Offices (“USAOs”) across the country are issuing warning letters to physicians and other prescribers (collectively, “Prescribers”) cautioning them about their opioid prescribing practices (the “Warning Letters”). In just the last week, the USAO for the Eastern District of Wisconsin sent warning letters to over 180 prescribers identified by Drug Enforcement Administration (“DEA”) data as prescribing opioids at relatively high levels. The Food and Drug Administration and the Federal Trade Commission have also been issuing their own warning letters to opioid marketers and distributors over the past several months, evidencing a concerted effort to combat the opioid epidemic on a number of fronts through various federal enforcement and regulatory efforts.
Continue Reading Compliance Risk Alert: Opioid Warning Letters issued by the U.S. Department of Justice Target Prescribers
About
Michael Paddock is a partner in the Governmental Practice in the firm's Washington, D.C. office.
More Posts
Blog Series Part 3: CMS Proposed Rule on Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Medicaid Fee-For-Service, and Medicaid Managed Care Programs for Years 2020 and 2021
CMS’ Medicare Advantage Overpayment Rule: Arbitrary, Capricious, and Vacated
The Department of Justice Delivers Some Good News to the Healthcare Industry: New False Claims Act Guidance Predicts More Challenges to Qui Tam Plaintiffs
DOJ Formalizes Guidance for Government Dismissal of Unmeritorious Qui Tam Suits
Supreme Court Preserves But Significantly Changes “Implied Certification” Theory of False Claims Act Liability
About
Michael Paddock is a partner in the Governmental Practice in the firm's Washington, D.C. office.